Jay Barth, MD, has been named chief medical officer of Ascidian Therapeutics, a biotech drug development company.
Dr. Barth has more than 25 years of experience in drug development and most recently served as chief medical officer for Lexeo Therapeutics, a gene therapy company, according to a March 20 news release from Ascidian.
In his new role, Dr. Barth will lead clinical development across the company's ophthalmology, neurological, neuromuscular and genetically defined diseases pipelines.